EMA Guidance on Trial Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
The impact of COVID-19 on ongoing trials, on opening a new trial site in an existing trial, ongoing recruitment and continued involvement of participants in the trial, or on starting of new trials needs to be considered. Read this EMA Guidance to learn more about managing your clinical trials during this pandemic.
Related Education Resources.
All ResourcesEuropean Roadmap to Lift COVID-19 Containment
Topics: Health Care, Strategic Planning
White Paper
Free
Reimagining Clinical Trial Surplus: Harnessing Donations to Close the Global Healthcare Gap
Topics: Supply Chain, Sustainability
White Paper
Free
FDA Policy for REMS Reqmts during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
